Related Experiment Video
Updated: Oct 21, 2025

Transverse Aortic Constriction in Mice
Published on: April 21, 2010
Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating
Jun Pan1, Zhenjun Xu1, Guanjun Guo1
1Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Insights
Circular RNA nuclear factor IX (circNfix) is downregulated in cardiac hypertrophy. Overexpressing circNfix protects against this condition by regulating the microRNA-145-5p/activating transcription factor 3 axis, suggesting it as a potential therapeutic target.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- RNA Biology
Background:
- Cardiac hypertrophy is a precursor to heart failure, but its progression mechanisms are not fully understood.
- Circular RNAs (circRNAs) are increasingly recognized for their roles in cardiovascular diseases.
- The specific function of circ_nuclear factor I X (circNfix) in cardiac hypertrophy remains largely unexplored.
Purpose of the Study:
- To investigate the role and mechanism of circNfix in the development of cardiac hypertrophy.
- To explore circNfix as a potential therapeutic target for cardiac hypertrophy.
Main Methods:
- Cardiac hypertrophy was induced in vitro using angiotensin II (Ang II) on cardiomyocytes.
- A mouse model of cardiac hypertrophy was established via transverse aortic constriction (TAC) surgery.
- RNA pull-down, luciferase reporter assays, and fluorescence in situ hybridization (FISH) were employed to elucidate the regulatory mechanism.
Main Results:
- circNfix expression was significantly downregulated in both Ang II-treated cardiomyocytes and TAC-induced mouse hearts.
- Overexpression of circNfix ameliorated cardiac hypertrophy in TAC-treated mice.
- Mechanistically, circNfix was found to bind miR-145-5p, indirectly regulating activating transcription factor 3 (ATF3) expression.
Conclusions:
- circNfix plays a protective role against cardiac hypertrophy by modulating the miR-145-5p/ATF3 pathway.
- circNfix represents a promising molecular target for the treatment of cardiac hypertrophy and subsequent heart failure.
Abstract:
Cardiac hypertrophy can cause heart failure. However, the mechanisms underlying the progression of cardiac hypertrophy remain unclear. Emerging evidence suggests that circular RNAs (circRNAs) play a critical role in cardiac hypertrophy. However, the association between circ_nuclear factor I X (circNfix) and cardiac hypertrophy remain largely unknown. Therefore, the aim of the present study was to explore the role of circNfix in cardiac hypertrophy. In order to detect the function of circNfix in cardiac hypertrophy, cardiomyocytes were stimulated with angiotensin II (Ang II) to mimic the pathogenesis of the disease. In addition, pressure overload-induced cardiac hypertrophy in a mouse model was established using transverse aortic constriction (TAC) surgery. The mechanism via which circNfix regulated cardiac hypertrophy was investigated using RNA pull-down and luciferase reporter assays, and fluorescence in situ hybridization (FISH). circNfix was downregulated in Ang II-treated cardiomyocytes. Similarly, circNfix expression was markedly downregulated in mice following TAC surgery. In addition, circNfix overexpression significantly prevented the progression of cardiac hypertrophy in TAC-treated mice. Luciferase activity and RNA pull-down assays indicated that circNfix could indirectly target activating transcription factor 3 (ATF3) by binding with microRNA (miR)-145-5p in cardiomyocytes. miR-145-5p overexpression or ATF3 knockdown could reverse the effects of circNfix in Ang II-treated mouse cardiomyocytes. circNfix attenuated pressure overload-induced cardiac hypertrophy by regulating the miR-145-5p/ATF3 axis. Therefore, circNfix may serve as a molecular target for cardiac hypertrophy treatment.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

